Dr. Reddy’s Lab get CRL from USFDA for NuvaRing, Copaxone

16 Aug 2019

Dr. Reddy's Laboratories has received complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its versions of NuvaRing and Copaxone. NuvaRing is a birth control device and Copaxone (glatiramer acetate injection) is a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Related Dr. Reddys Laboratories Ltd. Links:

Dr. Reddys Lab Share Price

5083.50 -43.65 (-0.85%) Sep 29, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 505.60
Dr. Reddys Lab 5083.50
Lupin 998.00
Piramal Enterprises 1253.15
Cadila Healthcare 387.55
View more..
Sensex vs Dr. Reddys Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback